<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454337</url>
  </required_header>
  <id_info>
    <org_study_id>2007-000162-20</org_study_id>
    <secondary_id>ANRS 138 EASIER</secondary_id>
    <nct_id>NCT00454337</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load</brief_title>
  <acronym>EASIER</acronym>
  <official_title>Randomized Non-inferiority Study Comparing a Strategy Maintaining Current Enfuvirtide-based Antiretroviral Therapy to a Strategy Replacing Enfuvirtide by an Integrase Inhibitor (Raltegravir) in HIV-1 Infected Subjects With Plasma Hiv-1 RNA Levels Below 400 Copies Per ml.ANRS 138 EASIER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Switching from enfuvirtide to raltegravir in the treatment of HIV-infected patients who
      sustain viral suppression with a combination therapy including enfuvirtide (or : with an
      enfuvirtide-based combination therapy)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients who have failed under the three main classes of antiretroviral agents (NRTI,
      NNRTI and PI) and in whom the control of viral replication in the plasma has ultimately been
      achieved with enfuvirtide, the aim is to sustain this virological success for as long as
      possible to thus enable satisfactory immune reconstitution, avoid further accumulation of
      viral mutations conferring resistance to the drugs and protect the patient from the risk of
      opportunistic disease and death.

      Indeed, enfuvirtide is the lead compound in the new class of antiretroviral drugs which
      inhibit the fusion of HIV-1 virus with its target cell. Its in vivo efficacy was demonstrated
      during the pivotal studies TORO 1 and 2. Despite its efficacy, maintaining long-term
      treatment with enfuvirtide is nonetheless difficult for patients because of the constraints
      related to twice-daily subcutaneous parenteral injections. Furthermore, these subcutaneous
      injections are associated with inflammatory reactions at the injection site in 98 per cent of
      patients, without any reduction in frequency or severity over time. It is thus critical for
      patients who are well controlled by enfuvirtide to be able to simplify their treatment by
      replacing enfuvirtide with another active compound taken by mouth, which would enable
      maintenance of the virological response and acceptable safety in patients who have usually
      failed under the three main classes of antiretroviral drugs. A new antiviral compound, viral
      integrase inhibitor called raltegravir, could be proposed instead of enfuvirtide.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm</measure>
    <time_frame>W24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of time to onset of virologic failure</measure>
    <time_frame>W24 and W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportions of pts with pVL under 50 and 400 cp per ml respectively at week 24 and week 48 ;</measure>
    <time_frame>W24 &amp; W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma viral mutations in the event of virologic failure, compared to HIV-DNA archived mutations at baseline;</measure>
    <time_frame>virologic failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in CD4 levels</measure>
    <time_frame>between W0 and W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of HIV-related events</measure>
    <time_frame>between W0 and W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug plasma and male genital tract pharmacokinetics;</measure>
    <time_frame>W24 &amp; W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and type of adverse events, including adverse reactions</measure>
    <time_frame>between W0 &amp; W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportions of discontinuing allocated treatment strategy</measure>
    <time_frame>between W0 &amp; W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life and adherence</measure>
    <time_frame>W4, W12, W24 and W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morphological and metabolic disorders outcome</measure>
    <time_frame>between W0 &amp; W48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Intensification arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>emtricitabine/TDF + efavirenz or lopinavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF + EFV or LPV/R +T20</intervention_name>
    <description>emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day</description>
    <arm_group_label>Intensification arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF + EFV or LPV/R</intervention_name>
    <description>emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)</description>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HIV-1 infection

          -  Treatment with a well-tolerated combination of antiretroviral drugs unchanged for at
             least 3 months, including enfuvirtide

          -  Absence of any uncontrolled opportunistic disease

          -  No restrictions on CD4 lymphocyte levels

          -  Plasma HIV-1 RNA below 400 copies per ml for at least 3 months (at least two
             consecutive tests below 400 copies per ml prior to inclusion in the study, not
             including that on W -4)

          -  For women of childbearing age, use of mechanical contraception during any sexual
             intercourse and negative pregnancy test (plasma ÃŸ HCG) at W -4

        Exclusion Criteria:

          -  HIV-2 infection

          -  Plasma HIV-1 RNA levels above 400 copies/ml on one occasion during the 3 months prior
             to screening (or the pre-inclusion visit at W -4)

          -  Poor compliance with antiretroviral therapy current at W -4

          -  Current treatment with an investigational drug (except cohort ATU)

          -  Patient previously treated with an integrase inhibitor in the context of a clinical
             study

          -  Woman who is pregnant or likely to become so, is breastfeeding or refuses to use
             contraception

          -  Multiple drug therapy ongoing or necessary in the foreseeable future for Kaposi's
             disease or lymphoma

          -  Treatment with interferon ongoing or necessary in the foreseeable future for chronic
             hepatitis B or C

          -  Acute hepatitis whatever the case, or decompensated cirrhosis

          -  Current treatment with interferon, interleukin or anti-HIV vaccine

          -  Any condition (including, but not limited to, the consumption of alcohol or drugs)
             which might, in the investigator's opinion, compromise the safety of treatment and/or
             patient compliance with the protocol

          -  Significant biological abnormalities (hemoglobin below 8g per dl, polynuclear
             neutrophils below 750 per mm3, platelets below 50,000 per mm3, serum creatinine above
             3 times the level deemed normal by the laboratory (N), ASAT or ALAT above 5N, serum
             lipase above 2N) and total bilirubin above 2N (except if the patient is receiving
             atazanavir or indinavir)

          -  Concomitant treatments including one or more compounds interacting with UGT1A1

               -  anti-infective agents: rifampicin/rifampin

               -  psychotropic/anti-epileptic drugs: phenytoin, phenobarbital.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie De Castro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Hopital Saint Louis Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean M Molina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Hopital saint Louis Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean P Aboulker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>INSERM SC10 Villejuif France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des maladies infectieuses et tropicales Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM, Molina JM. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother. 2011 Jul;55(7):3613-5. doi: 10.1128/AAC.01827-10. Epub 2011 May 16.</citation>
    <PMID>21576452</PMID>
  </results_reference>
  <results_reference>
    <citation>Barau C, Delaugerre C, Braun J, de Castro N, Furlan V, Charreau I, GÃ©rard L, Lascoux-Combe C, Molina JM, Taburet AM. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.</citation>
    <PMID>19995925</PMID>
  </results_reference>
  <results_reference>
    <citation>Delaugerre C, Charreau I, Braun J, NÃ©rÃ© ML, de Castro N, Yeni P, Ghosn J, Aboulker JP, Molina JM, Simon F; ANRS 138 study group. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS. 2010 Sep 24;24(15):2391-5. doi: 10.1097/QAD.0b013e32833d214c.</citation>
    <PMID>20683319</PMID>
  </results_reference>
  <results_reference>
    <citation>Boulet T, Pavie J, Charreau I, Braun J, Reynes J, Morlat P, Piroth L, Spire B, Molina JM, Aboulker JP; Easier-Anrs 138 Study Group. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). HIV Clin Trials. 2010 Sep-Oct;11(5):283-93. doi: 10.1310/hct1105-283.</citation>
    <PMID>21126958</PMID>
  </results_reference>
  <results_reference>
    <citation>Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM, Kuritzkes DR. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS. 2011 Mar 13;25(5):665-9. doi: 10.1097/QAD.0b013e3283445834.</citation>
    <PMID>21326075</PMID>
  </results_reference>
  <results_reference>
    <citation>Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28.</citation>
    <PMID>21712241</PMID>
  </results_reference>
  <results_reference>
    <citation>Delaugerre C, Braun J, Charreau I, Delarue S, Nere ML, de Castro N, May T, Marchou B, Simon F, Molina JM, Aboulker JP; ANRS 138-EASIER study group. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med. 2012 Oct;13(9):517-25. doi: 10.1111/j.1468-1293.2012.01002.x. Epub 2012 Mar 14.</citation>
    <PMID>22416781</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2007</study_first_submitted>
  <study_first_submitted_qc>March 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 infection</keyword>
  <keyword>enfuvirtide</keyword>
  <keyword>raltegravir</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Enfuvirtide</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

